文献速递肾小球疾病肾移植

免疫吸附治疗儿童肾移植后复发性局灶节段性肾小球硬化:法国多中心队列

Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该法国多中心回顾性队列纳入2011年1月至2014年6月间12例肾移植后早期复发原发性FSGS的儿童,排除遗传型FSGS,采用免疫吸附治疗。10例应答,其中2例部分缓解、8例完全缓解,蛋白尿在起始免疫吸附后前10次内快速下降。治疗3个月后,2例无需免疫吸附维持缓解,8例依赖免疫吸附,未报告严重不良反应。

要点

  • 儿童肾移植后早期复发FSGS采用免疫吸附,12例中10例应答。
  • 应答者中8例完全缓解、2例部分缓解,蛋白尿在前10次免疫吸附内快速下降。
  • 治疗3个月后8例依赖免疫吸附,2例无需免疫吸附维持缓解。

核心结论

  • 免疫吸附对儿童肾移植后复发性FSGS有效,但需前瞻性对照研究确认并优化管理。

研究设计与样本

  • 法国6个儿童肾移植中心2011年1月至2014年6月的回顾性队列,纳入12例早期复发FSGS并接受免疫吸附的儿童,排除遗传型FSGS。

主要发现

  • 12例中10例应答:2例部分缓解、8例完全缓解。
  • 蛋白尿在起始免疫吸附后前10次内快速下降。
  • 治疗3个月后,2例无需免疫吸附维持缓解,8例依赖免疫吸附。
  • 未报告严重不良反应。

关键数值与推荐

  • 复发定义为移植后肾病性蛋白尿。
  • 部分缓解定义为尿蛋白肌酐比小于0.2 g/mmol,完全缓解定义为小于0.05 g/mmol。
  • 复发发生于肾移植后0至21天。

临床怎么用

  • 对儿童肾移植后早期复发非遗传型FSGS可考虑免疫吸附控制蛋白尿。
  • 多数患者可能需依赖免疫吸附维持缓解,应规划长期治疗与监测。

局限性

  • 回顾性设计,样本量小(12例),来自6个中心。
  • 缺乏对照组,需前瞻性对照研究确认疗效并优化管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary focal segmental glomerulosclerosis (FSGS) frequently recurs after kidney transplantation (KTx) in children. This can lead to delayed graft loss. As the management of children with recurrent FSGS is not well established, apheresis strategies could be a cornerstone to control the disease. Immunoadsorption (IA) is a recent apheresis therapy. There have been few studies examining IA in this setting. We report the results of IA for management of recurrent FSGS after KTx in children in France. METHODS: We included all children treated with IA for early FSGS recurrence after KTx between January 2011 and June 2014 in France. We excluded genetic forms of FSGS. Patients' characteristics and technical data on IA were retrospectively collected. Recurrence was defined as nephrotic proteinuria during the post-transplantation period. Partial and complete remissions were defined when urine protein:creatinine ratios were less than 0.2 and 0.05 g/mmol, respectively. RESULTS: Twelve patients, from six paediatric KTx units, presenting with FSGS recurrence between 0 and 21 days after KTx were treated with IA. Ten of 12 children were responders: 2 achieved partial remission and 8 complete remission. The decrease of proteinuria rapidly occurred within the first 10 sessions after initiating IA. After 3 months of IA, two patients maintained remission without IA and eight became IA dependent. No severe side effects were reported. CONCLUSIONS: Our study reports on the efficacy of IA in the recurrence of FSGS after KTx in children. Further prospective controlled studies are required to confirm these results and to optimize the management of FSGS recurrence after paediatric KTx.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Allard L, Kwon T, Krid S, et al. Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort. Nephrol Dial Transplant. 2018. PMID: 28992235. doi:10.1093/ndt/gfx214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。